KRAS and non-small cell lung carcinoma: This study demonstrated that early clearance of KRAS G12C–mutant ctDNA predicted the clinical benefit of sotorasib in patients with advanced NSCLC, suggesting that dynamic monitoring of ctDNA levels also may anticipate sotorasib resistance.